Biology Reference
In-Depth Information
experimental myocardial infarction in rats.
Cardiovasc Drugs Ther 20(4):245-251
11. Moon C, Krawczyk M, Paik D, Coleman T,
Brines M, Juhaszova M, Sollott SJ, Lakatta
EG, Talan MI (2006) Erythropoietin, modified
to not stimulate red blood cell production,
retains its cardioprotective properties.
J Pharmacol Exp Ther 316(3):999-1005
12. Ahmet I, Tae HJ, Juhaszova M, Riordon DR,
Boheler KR, Sollott SJ, Brines M, Cerami A,
Lakatta EG, Talan MI (2011) A small non-
erythropoietic helix B surface peptide based
upon erythropoietin structure is cardioprotec-
tive against ischemic myocardial damage. Mol
Med
erythropoietin in the reperfused ischemic
heart: a potential role for cardiac fibroblasts.
J Biol Chem 279:20655-20662
20. Abdelrahman M, Sharples EJ, McDonald MC,
Collin M, Patel NS, Yaqoob MM, Thiemermann
C (2004) Erythropoietin attenuates the tissue
injury associated with hemorrhagic shock and
myocardial ischemia. Shock 22:63-69
21. Lipsic E, van der Meer P, Henning RH,
Suurmeijer AJ, Boddeus KM, van Veldhuisen
DJ, van Gilst WH, Schoemaker RG (2004)
Timing of erythropoietin treatment for cardio-
protection in ischemia/reperfusion. J Cardiovasc
Pharmacol 44:473-479
22. Rui T, Feng Q, Lei M, Peng T, Zhang J, Xu
M, Abel ED, Xenocostas A, Kvietys PR (2005)
Erythropoietin prevents the acute myocardial
inflammatory response induced by ischemia/
reperfusion via induction of AP-1. Cardiovasc
Res 65:719-727
23. Hirata A, Minamino T, Asanuma H, Sanada S,
Fujita M, Tsukamoto O, Wakeno M, Myoishi
M, Okada K, Koyama H, Komamura K,
Takashima S, Shinozaki Y, Mori H, Tomoike
H, Hori M, Kitakaze M (2005) Erythropoietin
just before reperfusion reduces both lethal
arrhythmias and infarct size via the phosphati-
dylinositol-3 kinase-dependent pathway in
canine hearts. Cardiovasc Drugs Ther
19:33-40
24. Xu B, Dong GH, Liu H, Wang YQ, Wu HW,
Jing H (2005) Recombinant human erythro-
poietin pretreatment attenuates myocardial
infarct size: a possible mechanism involves heat
shock Protein 70 and attenuation of nuclear
factor-kappa B. Ann Clin Lab Sci 35:161-168
25. Bullard AJ, Govewalla P, Yellon DM (2005)
Erythropoietin protects the myocardium
against reperfusion injury in vitro and in vivo.
Basic Res Cardiol 100:397-403
26. Kristensen J, Maeng M, Rehling M, Berg JS,
Mortensen UM, Nielsen SS, Nielsen TT
(2005) Lack of acute cardioprotective effect
from pre-ischaemic erythropoietin administra-
tion in a porcine coronary occlusion model.
Clin Physiol Funct Imaging 25:305-310
27. Liu X, Xie W, Liu P, Duan M, Jia Z, Li W, Xu
J (2006) Mechanism of the cardioprotection
of rhEPO pretreatment on suppressing the
inflammatory response in ischemia-reperfu-
sion. Life Sci 78:2255-2264
28. Nishihara M, Miura T, Miki T, Sakamoto J,
Tanno M, Kobayashi H, Ikeda Y, Ohori K,
Takahashi A, Shimamoto K (2006)
Erythropoietin affords additional cardiopro-
tection to preconditioned hearts by enhanced
phosphorylation of glycogen synthase kinase-3
beta. Am J Physiol Heart Circ Physiol
291:H748-H755
17(3-4):194-200.
doi:
10.2119/
13. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal
LS, Walton GB, Thompson RB, Petrofski JA,
Annex BH, Stamler JS, Koch WJ (2003) A
novel protective effect of erythropoietin in the
infarcted heart. J Clin Invest 112(7):999-1007
14. van der Meer P, Lipsic E, Henning RH,
Boddeus K, van der Velden J, Voors AA, van
Veldhuisen DJ, van Gilst WH, Schoemaker RG
(2005) Erythropoietin induces neovasculariza-
tion and improves cardiac function in rats with
heart failure after myocardial infarction. J Am
Coll Cardiol 46(1):125-133
15. Hale SL, Sesti C, Kloner RA (2005)
Administration of erythropoietin fails to
improve long-term healing or cardiac function
after myocardial infarction in the rat. J
Cardiovasc Pharmacol 46(2):211-215
16. Hirata A, Minamino T, Asanuma H, Fujita M,
Wakeno M, Myoishi M, Tsukamoto O, Okada
K, Koyama H, Komamura K, Takashima S,
Shinozaki Y, Mori H, Shiraga M, Kitakaze M,
Hori M (2006) Erythropoietin enhances neo-
vascularization of ischemic myocardium and
improves left ventricular dysfunction after
myocardial infarction in dogs. J Am Coll
Cardiol 48(1):176-184, Epub 2006 Jun 2
17. Chua S, Leu S, Lin YC, Sheu JJ, Sun CK,
Chung SY, Chai HT, Lee FY, Kao YH, Wu CJ,
Chang LT, Ko SF, Yip HK (2011) Early eryth-
ropoietin therapy attenuates remodeling and
preserves function of left ventricle in porcine
myocardial infarction. J Investig Med
59(3):574-586
18. Calvillo L, Latini R, Kajstura J, Leri A,
Anversa P, Ghezzi P, Salio M, Cerami A,
Brines M (2003) Recombinant human eryth-
ropoietin protects the myocardium from
ischemia-reperfusion injury and promotes
beneficial remodeling. Proc Natl Acad Sci
USA 100:4802-4806
19. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson
RB, Petrofski JA, Matsumoto A, Stamler JS,
Koch WJ (2004) Cardioprotective effects of
Search WWH ::
Custom Search